Diagnostic imaging company RadNet (NASDAQ:RDNT) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 13.5% year on year to $477.1 million. On the other hand, the company’s full-year revenue guidance of $1.94 billion at the midpoint came in 1.2% below analysts’ estimates. Its GAAP profit of $0.07 per share was 40.7% below analysts’ consensus estimates.
Solar tracking systems manufacturer Array (NASDAQ:ARRY) announced better-than-expected revenue in Q4 CY2024, but sales fell by 19.4% year on year to $275.2 million. The company expects next quarter’s revenue to be around $265 million, coming in 26.3% above analysts’ estimates. Its non-GAAP profit of $0.16 per share was in line with analysts’ consensus estimates.
Traffic solutions company Verra Mobility (NYSE:VRRM) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 5% year on year to $221.5 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $930 million at the midpoint. Its non-GAAP profit of $0.33 per share was 11.2% above analysts’ consensus estimates.
The cruise operator released earnings in line with analyst expectations and forecast further growth ahead, but investors were cautious.
Casino, tavern, and slot machine operator Golden Entertainment (NASDAQ:GDEN) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 28.8% year on year to $164.2 million. Its GAAP profit of $0.10 per share was 50.3% below analysts’ consensus estimates.
Laser company nLIGHT (NASDAQ:LASR) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 8.7% year on year to $47.38 million. On the other hand, the company expects next quarter’s revenue to be around $48 million, close to analysts’ estimates. Its non-GAAP loss of $0.30 per share was 51.9% below analysts’ consensus estimates.
Real estate technology company Redfin (NASDAQ:RDFN) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 12% year on year to $244.3 million. On the other hand, next quarter’s revenue guidance of $219.5 million was less impressive, coming in 10.4% below analysts’ estimates. Its GAAP loss of $0.29 per share was 21% below analysts’ consensus estimates.
Medical device company ICU Medical (NASDAQ:ICUI) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 7.1% year on year to $629.8 million. Its non-GAAP profit of $2.11 per share was 42.4% above analysts’ consensus estimates.
Behavioral health company Acadia Healthcare (NASDAQ:ACHC) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.2% year on year to $774.2 million. Next quarter’s revenue guidance of $770 million underwhelmed, coming in 5.8% below analysts’ estimates. Its non-GAAP profit of $0.64 per share was 10.4% below analysts’ consensus estimates.
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per share was 1.9% below analysts’ consensus estimates.